We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
NGVT Stock Rallies 31% in a Year: What's Driving the Upside?
Read MoreHide Full Article
Key Takeaways
Ingevity's portfolio transformation through divestitures and acquisitions is reshaping its growth strategy.
NGVT's cash flow gains and debt reduction lowered leverage to 2.5X while supporting capital returns.
Ingevity sees growth opportunities from PFAS contracts, biofuels applications and capacity expansions.
Ingevity Corporation’s (NGVT - Free Report) shares have rallied 30.6% in the past year. The company has also outperformed the Zacks Chemical - Specialty industry’s 0.2% growth over the same time frame. Ingevity’s portfolio optimization actions, investments in capacity and debt reduction supported by higher cash flows have boosted investor confidence in its long-term growth prospects.
Image Source: Zacks Investment Research
Let’s take a look at the factors that are driving NGVT stock.
Portfolio Transformation and New Growth Opportunities
Ingevity has been benefiting from its portfolio transformation strategy, supported by strategic divestitures, acquisitions and successful repositioning efforts. The divestiture of the Industrial Specialties business and Road Markings product line, along with the ongoing sale process for the APT business, is optimizing the company’s portfolio and increasing focus on higher-return opportunities.
The elimination of $10 million of stranded costs and acquisitions of Georgia-Pacific’s pine chemicals business, Capa caprolactone business and Ozark Materials are further strengthening the portfolio through manufacturing optimization, lower logistics costs, new technology platforms and more market opportunities. Meanwhile, PFAS filtration contract, European biofuels applications for TOFA and capacity expansions in soy-based fatty acids, caprolactone and polyols are creating opportunities for long-term growth.
Cash Flow and Capital Allocation Support Returns
Improving cash generation and disciplined capital allocation have also supported Ingevity’s performance. In the second quarter, free cash flow excluding the litigation settlement payment reached approximately $89 million, while debt reduction lowered leverage to 2.5X. The company’s focus on further reducing leverage to 2X-2.5X, alongside the plan to repurchase $300 million of shares through 2027, underscores its commitment to strengthening the balance sheet while returning capital to shareholders.
Other top-ranked stocks in the Basic Materials space are Reliance, Inc. (RS - Free Report) , Avient Corporation (AVNT - Free Report) and Kronos Worldwide, Inc. (KRO - Free Report) .
The Zacks Consensus Estimate for RS’ 2026 earnings is pegged at $22.53 per share, indicating a 58% year-over-year increase. RS’shares have gained 36.7% over the past year.
The Zacks Consensus Estimate for AVNT’s current-year earnings is pinned at $3.2 per share, indicating a 13.5% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 3.4%. AVNT’sshares have gained 27.3% over the past year.
The Zacks Consensus Estimate for KRO’s 2026 earnings is pegged at 35 cents per share, indicating a rise of 136.5% year over year. KRO’s earnings beat the Zacks Consensus Estimate in two of the trailing four quarters while missing it in the rest, with an average surprise of 34%.
View the Zacks #1 Rank List
Image: Bigstock
NGVT Stock Rallies 31% in a Year: What's Driving the Upside?
Key Takeaways
Ingevity Corporation’s (NGVT - Free Report) shares have rallied 30.6% in the past year. The company has also outperformed the Zacks Chemical - Specialty industry’s 0.2% growth over the same time frame. Ingevity’s portfolio optimization actions, investments in capacity and debt reduction supported by higher cash flows have boosted investor confidence in its long-term growth prospects.
Image Source: Zacks Investment Research
Let’s take a look at the factors that are driving NGVT stock.
Portfolio Transformation and New Growth Opportunities
Ingevity has been benefiting from its portfolio transformation strategy, supported by strategic divestitures, acquisitions and successful repositioning efforts. The divestiture of the Industrial Specialties business and Road Markings product line, along with the ongoing sale process for the APT business, is optimizing the company’s portfolio and increasing focus on higher-return opportunities.
The elimination of $10 million of stranded costs and acquisitions of Georgia-Pacific’s pine chemicals business, Capa caprolactone business and Ozark Materials are further strengthening the portfolio through manufacturing optimization, lower logistics costs, new technology platforms and more market opportunities. Meanwhile, PFAS filtration contract, European biofuels applications for TOFA and capacity expansions in soy-based fatty acids, caprolactone and polyols are creating opportunities for long-term growth.
Cash Flow and Capital Allocation Support Returns
Improving cash generation and disciplined capital allocation have also supported Ingevity’s performance. In the second quarter, free cash flow excluding the litigation settlement payment reached approximately $89 million, while debt reduction lowered leverage to 2.5X. The company’s focus on further reducing leverage to 2X-2.5X, alongside the plan to repurchase $300 million of shares through 2027, underscores its commitment to strengthening the balance sheet while returning capital to shareholders.
Ingevity Corporation Price and Consensus
Ingevity Corporation price-consensus-chart | Ingevity Corporation Quote
NGVT’s Zacks Rank & Other Key Picks
NGVT currently carries a Zacks Rank #2 (Buy).
Other top-ranked stocks in the Basic Materials space are Reliance, Inc. (RS - Free Report) , Avient Corporation (AVNT - Free Report) and Kronos Worldwide, Inc. (KRO - Free Report) .
AVNT sports a Zacks Rank #1 (Strong Buy) at the moment, while RS and KRO carry a Zacks Rank #2 each at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for RS’ 2026 earnings is pegged at $22.53 per share, indicating a 58% year-over-year increase. RS’shares have gained 36.7% over the past year.
The Zacks Consensus Estimate for AVNT’s current-year earnings is pinned at $3.2 per share, indicating a 13.5% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 3.4%. AVNT’sshares have gained 27.3% over the past year.
The Zacks Consensus Estimate for KRO’s 2026 earnings is pegged at 35 cents per share, indicating a rise of 136.5% year over year. KRO’s earnings beat the Zacks Consensus Estimate in two of the trailing four quarters while missing it in the rest, with an average surprise of 34%.